On April 24, the CDE website showed that Hansoh PharmaHS-20089 for Injection Proposed for Inclusion in Breakthrough Therapy Designation, for the Treatment ofPlatinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancerPatient.Screenshot source: CDE official websiteHS-20089 is a novel B7-H4 ADC with a topoisomerase inhibitor. (TOPOi) Payload. B7-H4 is a transmembrane glycoprotein in the B7 superfamily, with limited expression in normal tissues but highly expressed in various cancers.In October 2023, GSK and Hansoh Pharma reached an agreement on this drug.Exclusive License Agreement`, GSK obtains the global exclusive rights to the drug.`(Excluding mainland China, Hong Kong, Macao and Taiwan), to advance the development and commercialization of HS-20089.According to the terms of this agreement, Hansoh will receive$85 millionThe prepayment, and is eligible to receive up to$1.485 billionThe milestone revenue. After the commercialization of HS-20089, GSK will also pay tiered royalties based on global net sales outside of mainland China, Hong Kong, Macao, and Taiwan.Insight database shows that there are 10 entries globally.B7-H4 ADC Pipeline Under Research(Only active status is counted), six products have entered the clinical stage. Among them, Hansoh Pharma's HS-20089 is the most advanced.The FirstEntering Phase III Clinical TrialsB7-H4 ADC, the rest are all in the early clinical stage.Screenshot source: Insight database
Cover Source:Corporate LogoDisclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment options. If necessary, please consult and contact正规医疗机构.PR Article Coordination: WeChat insightxbSubmissionWeChat: insightxb; Email: insight@dxy.cn
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)